BRCA1 and BRCA2 Gene Mutation Testing for Hereditary Breast and Ovarian Cancer Risk

This test is a laboratory analysis, usually performed on a blood or saliva sample, that checks your BRCA1 and BRCA2 genes for inherited changes, called mutations, that can significantly increase your lifetime risk of developing breast, ovarian, and certain other cancers.

The Adult Diffuse Glioma Gene Mutation Test is a molecular genetics test that looks for specific genetic changes (mutations) in tumor tissue from adults with diffuse gliomas. These are a type of brain tumor that arises from glial cells in the brain. The test examines DNA from the tumor sample to identify mutations in genes known to be important for diagnosis, prognosis, and treatment planning.

This test is performed to determine whether you carry an inherited BRCA1 or BRCA2 mutation. Knowing your genetic status helps your doctor estimate your personal cancer risk, plan appropriate screening and prevention strategies, guide treatment decisions if cancer is already diagnosed, and identify relatives who may also benefit from testing.

This test is performed on tumor tissue removed during biopsy or surgery. It helps doctors: (1) Determine the exact type of glioma (such as astrocytoma, oligodendroglioma, or glioblastoma), (2) Predict how the tumor may behave (aggressiveness), (3) Estimate how patients may respond to specific treatments, and (4) Guide decisions about chemotherapy, radiation therapy, and targeted therapies.

The laboratory examines the complete BRCA1 and BRCA2 genes for disease-causing changes, including small insertions, deletions, and larger rearrangements. These inherited mutations are associated with hereditary breast and ovarian cancer syndrome and may also increase the risk of pancreatic, prostate, and melanoma cancers.

The test typically looks for several key mutations: IDH1 and IDH2 mutations (isocitrate dehydrogenase genes), 1p/19q co-deletion (chromosomal loss), MGMT promoter methylation (affects chemotherapy response), TERT promoter mutations, and ATRX loss. Each mutation provides different information about the tumor's classification and expected behavior.

A sample is most often collected through a simple blood draw from a vein in your arm, although a saliva sample collected in a sterile container may sometimes be used instead. The procedure takes only a few minutes, requires no special preparation or fasting, and the sample is then sent to a certified genetics laboratory for analysis.

The tissue sample is collected during a surgical procedure to remove part or all of the brain tumor (biopsy or resection). The neurosurgeon obtains the tissue, which is then sent to a specialized laboratory for molecular genetic analysis. The sample is processed to extract DNA or RNA, which is then analyzed using techniques like PCR, sequencing, or other molecular methods.